Angiogenesis is a fundamental process to normal and abnormal tissue growth and repair, which consists of recruiting endothelial cells toward an angiogenic stimulus. The cells subsequently proliferate and differentiate to form endothelial tubes and capillarylike structures. Little is known about the metabolic adaptation of endothelial cells through such a transformation. We studied the metabolic changes of endothelial cell activation by growth factors using human umbilical vein endothelial cells (HUVECs), [1,2-13 C 2 ]-glucose and mass isotopomer distribution analysis. The metabolism of [1,2-13 C 2 ]-glucose by HUVEC allows us to trace many of the main glucose metabolic pathways, including glycogen synthesis, the pentose cycle and the glycolytic pathways. So we established that these pathways were crucial to endothelial cell proliferation under vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) stimulation. A specific VEGF receptor-2 inhibitor demonstrated the importance of glycogen metabolism and pentose cycle pathway. Furthermore, we showed that glycogen was depleted in a low glucose medium, but conserved under hypoxic conditions. Finally, we demonstrated that direct inhibition of key enzymes to glycogen metabolism and pentose phosphate pathways reduced HUVEC viability and migration. In this regard, inhibitors of these pathways have been shown to be effective antitumoral agents. To sum up, our data suggest that the inhibition of metabolic pathways offers a novel and powerful therapeutic approach, which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis.
Angiogenesis is a fundamental process to normal and abnormal tissue growth and repair, which consists of recruiting endothelial cells toward an angiogenic stimulus. The cells subsequently proliferate and differentiate to form endothelial tubes and capillarylike structures. Little is known about the metabolic adaptation of endothelial cells through such a transformation. We studied the metabolic changes of endothelial cell activation by growth factors using human umbilical vein endothelial cells (HUVECs), [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]-glucose and mass isotopomer distribution analysis. The metabolism of [1,2-13 C 2 ]-glucose by HUVEC allows us to trace many of the main glucose metabolic pathways, including glycogen synthesis, the pentose cycle and the glycolytic pathways. So we established that these pathways were crucial to endothelial cell proliferation under vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) stimulation. A specific VEGF receptor-2 inhibitor demonstrated the importance of glycogen metabolism and pentose cycle pathway. Furthermore, we showed that glycogen was depleted in a low glucose medium, but conserved under hypoxic conditions. Finally, we demonstrated that direct inhibition of key enzymes to glycogen metabolism and pentose phosphate pathways reduced HUVEC viability and migration. In this regard, inhibitors of these pathways have been shown to be effective antitumoral agents. To sum up, our data suggest that the inhibition of metabolic pathways offers a novel and powerful therapeutic approach, which simultaneously inhibits tumor cell proliferation and tumor-induced angiogenesis.
Introduction
One of the critical stages in tumor growth is neovascularization. The angiogenic impulse is promoted by tumor expression of proangiogenic proteins, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), interleukin-8, platelet-derived growth factor and transforming growth factor-beta, among others. The combined action of these factors on endothelial cells leads to the acquisition of a specific phenotype, which allows endothelial cells to migrate toward an angiogenic stimulus, proliferate and differentiate into capillarylike structures. Concretely, VEGF, which is highly upregulated in most human cancers (1) , has emerged in the last few years as the crucial rate-limiting step in the regulation of normal and abnormal angiogenesis (2) . Therefore, VEGF and its receptor have been exploited in antiangiogenic therapies that are already successfully applied in clinical settings (3) (4) (5) . However, although patients treated with VEGF inhibitors may survive longer, there is emerging evidence that VEGF may be replaced by other angiogenic pathways as the disease progresses (5, 6) . Thus, a better understanding of the underlying metabolic changes that supports tumor angiogenesis downstream of VEGF activation is necessary to design complementary strategies that can overcome resistance to angiogenic therapies. In fact, in spite of the increasing recognition that the metabolome represents the end point of many cellular events (7) (8) (9) , little is known about the metabolic changes underlying endothelial cell activation during angiogenesis (10) (11) (12) (13) . A better knowledge of the specific adaptation of metabolic network fluxes occurring downstream of the growth factor activation of endothelial cells could aid identification of metabolic enzyme drug targets. Such targets might help to overcome the developing resistance to VEGF-targeted therapies. Accurate substrate flow characterization of the activated endothelial cells in the angiogenic process may permit the design of effective, targeted antiangiogenic drugs acting downstream of the VEGF receptors.
Metabolic changes underlying tumor cell metabolism have been extensively studied in recent decades (14) (15) (16) and successful strategies for inhibiting the pathways on which cancer cells are strongly dependent have been proposed. In particular, inhibition of nucleic acid synthesis has been shown to be successful in chemotherapy (17) . Recently, it has been demonstrated in different tumor cell lines that pentose phosphate pathway (PPP) inhibition results in an effective decrease in tumor cell proliferation (18) (19) (20) (21) (22) . Moreover, it has been proposed that inhibition of normally enhanced tumor cell glycolysis can be a novel strategy for anticancer treatment (23, 24) or for overcoming the drug resistance associated with mitochondrial respiratory defects and hypoxia (23, 25) .
Stable isotope-based dynamic metabolic profiling using gas chromatography/mass spectrometry is a powerful new tool of great use in drug development (8) . In particular, the use of glucose labeled at the first two carbon positions with the stable isotope 13 C has been shown to be effective in revealing detailed substrate flow and distribution patterns in the complex metabolic network of different tumoral and non-tumoral cells. Recent examples of the strength of this approach include the elucidation of the metabolic mechanism underlying butyrate-induced cell differentiation (26) and the characterization of distinctive metabolic profiles that correlate with different point mutations in K-ras oncogene, which confer different degrees of aggressiveness in vivo, proving how the most aggressive mutations had an increased glycolytic rate (27) . In the present study, we used human umbilical vein endothelial cells (HUVECs) as an angiogenic model. We adopted a mass isotope distribution analysis approach with [1,2-13 C 2 ]-glucose tracer labeling to reveal the mechanisms of endothelial cells' metabolic network in response to the activation produced by the angiogenic stimulus of different growth factors. The metabolism of [1,2-13 C 2 ]-glucose by HUVEC allows us to trace many of the main glucose metabolic pathways, including glycogen synthesis, the pentose cycle pathways and the glycolytic pathways. To examine the downstream effect of VEGF, we used a well-known vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor, 5-diarylureaoxy-benzimidazole, which has also shown effects on Tie-2 receptors (28). This inhibitor allowed us to analyze the flux changes downstream of a specific inhibition of the angiogenic stimulus. The characterization of the effects of VEGFR-2 inhibitors at metabolic level contributes to the design of new therapeutic strategies for overcoming drug resistance. Such strategies are based on targeting the appropriate metabolic pathways, which mimic the effect of direct receptor inhibition on the metabolic network.
Materials and methods
Cell culture conditions HUVECs (AdvanCell, Barcelona, Spain) were cultured on gelatin at 37°C in a humidified atmosphere of 5% CO 2 and 95% air in endothelial cell basal medium (EBM) (Clonetics, San Diego, CA) and supplemented with endothelial cell growth medium (EGM) SingleQuots (Clonetics) and 10% fetal calf serum (FCS) (Biological Industries, Kibbutz Beit Ha'Emek, Israel). In these standard conditions, a 7.4-fold change with respect to the initial cell number was observed at 72 h.
Specifically activated cell growth assay for the mass isotopomer distribution analysis analysis Cells grown to 80-90% confluence were removed from the flask using 0.025% trypsin/ethylenediaminetetraacetic acid (Gibco, Invitrogen, Carlsbad, CA) at room temperature. Cells were seeded at a density of 4 Â 10 5 onto gelatineprecoated 75 cm 2 petri dishes (Falcon, BD biosciences, Franklin Lakes, NJ) in EGM (5 mmol/l glucose) and supplemented with EGM SingleQuots and 10% FCS for 24 h. The incubation medium was then removed and the plates were washed twice with Hanks' balanced salt solution (Clonetics). Specifically activated cell growth media was then added to the cell culture. This media contained EBM supplemented with 10 ng/ml VEGF (R&D systems, Minneapolis, MN) or 0.3 ng/ml basic FGF plus 2% FCS supplemented with 3 lg/ml heparin, 1 lg/ml hydrocortisone and 10 mmol/l of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]-glucose (50% isotope enrichment, Isotec, Sigma-Aldrich, St. Louis, MO). The inhibitor of VEGFR-2, 5-diarylurea-oxy-benzimidazole, was used at a final concentration of 85 nM. Cell cultures were incubated for 72 h. After the incubations, cells were centrifuged (1350 r.p.m. for 5 min) to obtain the incubation medium and cell pellets. At the end of the experiment, the final cell numbers were measured with a hemocytometer. To determine glycogen content, cells were immediately frozen in liquid nitrogen before being processed.
Glucose and lactate concentration
The glucose and lactate concentrations in the culture medium were determined as described previously (29, 30 ) using a Cobas Mira Plus chemistry analyzer (HORIBA ABX, Montpellier, France) at the beginning and at the end of the incubation time, to calculate glucose consumption and lactate production.
Lactate isotopomeric analysis
Lactate from the cell culture medium was extracted by ethyl acetate after acidification with HCl. Lactate was derivatized to its propylamideheptafluorobutyric form and the m/z 328 (carbons 1-3 of lactate, chemical ionization) was monitored as described (31) .
RNA ribose isotopomeric analysis RNA ribose was isolated by acid hydrolysis of cellular RNA after Trizol (Invitrogen, Carlsbad, CA) purification of cell extracts. Ribose isolated from RNA was derivatized to its aldonitrile acetate form using hydroxylamine in pyridine and acetic anhydride. The ion cluster around the m/z 256 (carbons 1-5 of ribose, chemical ionization) was monitored to find the molar enrichment and positional distribution of 13 C labels in ribose (31) .
Glycogen content determination and isotopomeric analysis
The glycogen content in frozen cell monolayers obtained from HUVEC was extracted as described previously (32) , by direct digestion of sonicated extracts with amyloglucosidase (Sigma-Aldrich, St. Louis, MO). The glycogen was then purified using a tandem set of Dowex-1X8/ Dowex-50WX8 (Sigma) ion exchange columns. For the isotopomeric analysis, the glycogen was converted to its glucose aldonitrile pentaacetate derivative as described previously (33) and the ion cluster around m/z 328 was monitored. Measurement of the glycogen content was carried out using the isotopomer [U- Gas chromatography/mass spectrometry Mass spectral data were obtained on an HP5973 mass selective detector connected to an HP6890 gas chromatograph. The settings were as follows: gas chromatography inlet 230°C; transfer line 280°C; mass spectrometry source 230°C and mass spectrometry quad 150°C. An HP-5 capillary column (30 m length, 250 mm diameter and 0.25 mm film thickness) was used to analyze glucose, ribose and lactate.
Hypoxic or hypoglycaemic conditions
To determine glycogen content under hypoxic or hypoglycaemic conditions, HUVECs were seeded at a density of 1 Â 10 6 onto 75 cm 2 petri dishes (Falcon) in EGM (5 mmol/l glucose) supplemented with EGM SingleQuots and 10% FCS for 24 h. The incubation medium was then removed and specifically activated cell growth media added in normoxic (37°C in a humidified atmosphere of 5% CO 2 and 95% air), hypoxic (37°C in a humidified atmosphere of 5% CO 2 , 1% O 2 ) or hypoglycaemic conditions [EGM 10 mmol/l glucose as a positive control, Dulbecco's modified Eagle's medium (DMEM; Sigma) 10 mmol/l glucose supplemented with EGM SingleQuots and 10% FCS as a negative control and DMEM without glucose supplemented with EGM SingleQuots and 10% FCS]. Cells were counted after 24 h. The medium was stored for subsequent analyses of glucose consumption and lactate production, as described above. In parallel, cell monolayers were immediately frozen in liquid nitrogen for glycogen determinations. Glycogen was extracted and quantified as described previously (34), with 30% (wt/vol) KOH and Whatman 31ET paper to precipitate the glycogen. Glucose released from glycogen was measured enzymatically in a Cobas Mira Plus chemistry analyzer (HORIBA ABX) and then corrected by protein content.
Cell viability assay
This assay was performed using a variation of the method described by Mosmann (35), as specified in Matito et al. (36) . For this assay, 3 Â 10 3 HUVEC cells/well were cultured on 96-well plates. Inhibitors CP-320626, G5 and O1 were added from 10 to 100 lM for 48 h. Relative cell viability was measured by absorbance on an enzyme-linked immunosorbent assay plate reader (Tecan Sunrise MR20-301, TECAN, Männedorf, Switzerland) at 550 nm.
Inhibitor CP-320626, kindly provided by Pfizer (New York City, NY) is an indole-2-carboxamide that binds at the dimmer interface site of glycogen phosphorylase, which was recently identified as a new allosteric site by X-ray crystallographic analysis (37, 38) . G5 and O1 were kindly supplied by Jaime Rubio from the University of Barcelona. Molecular modeling has been used in the development of these novel compound inhibitors of glucose-6-phosphate dehydrogenase and transketolase, respectively.
Migration assay
Migration assays were performed as described previously (39) , with the following modifications: 24-well cell culture plates (Falcon) were used with light-opaque polyethylene terephthalate membrane filter inserts with 8 mm pores (Transwell HTS FluoroBlokTM Multiwell Insert Systems from Becton Dickinson, Franklin Lakes, NJ). The upper and lower surfaces of the Transwell membranes were coated for 2 h at 37°C with 15 lg/ml type I Collagen. HUVECs were (5 Â 10 4 cells) suspended in 100 ll of EBM, and in absence of serum or other supplements, were seeded after coating onto the upper side of each Transwell chamber and placed 4 h at 37°C. Then, 500 ll of the inhibitors at IC50 (i.e. concentration at which the cell viability is 50% of the control calculated from Figure 4A : 40 lM of CP-320626, 30 lM of G5 and 25 lM of O1) and at 10 Â IC50 in EBM with 10% FCS and supplements were added to the lower compartment of the 24-well plates to test their inhibitory effect. After 4 h at 37°C, cells that had migrated to the lower side of the transwell were incubated with 5 mM Calcein-AM (Calbiochem, MERCK, Whitehouse Station, NJ) for 25-30 min at 37°C. Migrated cells were counted under a light microscope at a magnification of Â10.
Results

VEGF and FGF trigger a common characteristic metabolic changes in HUVECs
Lactate in the cell culture medium, the secreted product of glycolysis, was used to determine the contribution of glycolysis and the oxidative PPP to the central glucose metabolism. The unlabeled species (m0) represents the corrected lactate mass isotopomer distribution without the 13 C label; m1 represents the distribution with one 13 C label and m2 with two 13 C labels. The species m2 originates from glucose that is converted to lactate directly by glycolysis. In contrast, m1 originates from glucose metabolized by direct oxidation via the oxidative steps of the PPP, which is then recycled to glycolysis via the non-oxidative pentose cycle. Thus, we can calculate the PC parameter, which gives us an idea of pentose cycle use (as a percentage) with respect to glycolysis (31) . FGF activation provoked greater proliferation than Metabolic modulation underlying angiogenesis VEGF activation (Figure 1) . Therefore, the concentration of lactate secreted into the medium was higher in FGF-activated HUVECs (data not shown). Consequently, we observed a slight increase in 13 C-enriched lactate after FGF activation, with respect to VEGF (Table 1A, upper panel), measured as P mn 5 m1 þ 2 Â m2, a parameter that represents the average number of 13 C atoms per molecule. However, the flux balance (PC parameter) was not significantly altered, indicating a similar metabolic lactate pattern after both FGF and VEGF activation. Moreover, unlabeled lactate (m0) accumulated in similar amounts. This confirmed that the utilization of other carbon sources via degradation of the amino acids glutamine (glutaminolysis) and serine (serinolysis) is also maintained in HUVECs independently of the two growth factor activation pathways.
Due to the characteristics of the PPP, label incorporation into ribose occurred with the isotopomers m1 and m2 but also m3 and m4 species can be found. m1 is formed when [1,2-13 C 2 ]-glucose is decarboxylated by the oxidative branch of the PPP. m2 is synthesized by the reversible non-oxidative branch of the cycle. The combination of these two branches generates m3 and m4 species. The total label incorporation or 13 
oxidative branch to be formed, and m2, m3 and m4 species require the nonoxidative branch (twice in m4). In Table IB (upper panel) , a representative isotopomeric distribution of a single experiment is displayed. Significantly, similar traffic of glucose through the PPP was observed after either FGF or VEGF activation. As we noticed for lactate, the higher proliferation rate caused by FGF activation (Figure 1 ) caused a slight increase in 13 C enrichment ( P mn), with respect to VEGFactivated cells. However, the flux balance through the two branches of the pentose cycle (ox:non-ox ratio) was very similar and did not present consistent differences in the replicates performed.
High, similar glycogen concentrations were found in HUVECs under all the culture conditions. 13 C labeling was found in glycogen reservoirs. The analysis of glucose isotopomer distribution obtained from glycogen displayed only m0 and m2 species, indicating that the glycogen carbon source is glucose from the culture medium. A representative 13 C enrichment of glycogen after FGF or VEGF activation, measured as P mn 5 2 Â m2, is depicted in Figure 2A (black bars). Since initial glycogen reservoirs were not labeled, 13 C incorporation into glycogen from glucose increases with time and is dependent on the proliferation rate, as the cells have to replenish their glycogen content. Thus, as observed for lactate and ribose, there was a higher concentration of labeled glucose in glycogen after FGF activation than after VEGF activation, due to its higher proliferation rate (Figure 1 ).
Inhibition of VEGFR-2 decreases HUVEC proliferation via specific pathways activated by VEGF 5-Diarylurea-oxy-benzimidazole is a well-known VEGFR-2 inhibitor. It is often used to investigate the link between receptor activation and signaling pathways. The use of 5-diarylurea-oxy-benzimidazole allows us to study whether the characteristic, activated HUVEC metabolic pattern described above is the downstream effect of receptor activation-signaling pathways. The inhibitor caused $30% of proliferation inhibition when HUVECs were activated with VEGF and, unexpectedly, 20% of proliferation inhibition when cells were activated with FGF ( Figure 1) . Interestingly, inhibitor treatment did not affect the metabolic network when HUVEC activation was mediated by FGF; meanwhile, VEGF-activated cells suffered changes in ribose and glycogen metabolism. Thus, meanwhile, the RNA ribose isotopomeric distribution was not affected by the inhibitor in the three experiments performed when FGF was the activator (Table IB, lower Fig. 1 . Normalized cell counts with respect to the initial cell number. FGF activation induced higher proliferation rates than VEGF activation. The inhibitor (I: 5-diarylurea-oxy-benzimidazole) caused a decrease in both VEGF-and FGF-treated cells. However, this was relatively more pronounced when VEGF was used to activate HUVECs. Data are presented as mean ± SD of three independent experiments, 221 Â 113 mm (600 Â 600 DPI). 13 C enrichment ( P mn) and the oxidative:non-oxidative ratio in RNA ribose. HUVECs activated by either VEGF or FGF activation use the PPP in a similar way (upper panel). Inhibitor I treatment (lower panel) caused a significant decrease in the total incorporation from glucose to ribose ( P mn) in VEGF activation. This decrease was mainly determined by the inhibition of the oxidative branch of the PPP. Significance was tested using a non-parametric MannWhitney W-test to compare the medians of each independent experiment, considering 99% as a confident level. Significant differences ( ÃÃ ) were consistent in the three independent experiments.
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panel-in the single experiment depicted in Table IB , there was a slight increase in ribose 13 C enrichment when 5-diarylurea-oxybenzimidazole was added to FGF-activated HUVECs, but this increase was not statistically significant in the replicates), RNA ribose showed a significant and consistent decrease in 13 C enrichment ( P mn) when 5-diarylurea-oxy-benzimidazole was added to VEGFactivated cells (Table IB, lower panel) . Similar isotopomeric distribution patterns were found in all the experiments performed. Whereas the m2 proportion did not present significant changes, m1 decreased after the treatment with 5-diarylurea-oxy-benzimidazole, which caused a small but significant decrease in ox:non-ox ratio of PPP.
Similarly, although the inhibitor caused proliferation decrease in VEGF-and FGF-activated cells (Figure 1) , glycogen synthesis and turnover was also only affected by 5-diarylurea-oxy-benzimidazole in VEGF-activated cells. The 13 C enrichment of glycogen decreased significantly and consistently when the inhibitor was added. To deeper study of this marked decrease in label incorporation into glycogen when 5-diarylurea-oxy-benzimidazole was added to VEGF-activated HUVECs, the glycogen content was measured by gas chromatography/mass spectrometry procedures using an internal standard. Figure  2B shows that the glycogen content of VEGF-activated cells increased when the cells were treated with 5-diarylurea-oxy-benzimidazole, indicating that glycogen degradation was inhibited.
Curiously, the VEGFR-2 inhibitor treatment did not affect lactate label distribution. Moreover, neither 13 C enrichment nor flux balance (PC parameter) presented significant differences after either VEGF or FGF activation, indicating that the metabolic pattern detected in lactate was not dependent on specific endothelial activation (Table IA,  lower panel) .
Glycogen reservoirs are mobilized under hypoglycaemic conditions, but not under hypoxic conditions Activated endothelial cells induced by tumors are recruited toward hypoxic and hypoglycaemic environments. To better understand the role of HUVEC glycogen reservoirs in physiological conditions, cells were cultured in a glucose-free medium. For this specific culture condition, 10 mM glucose DMEM was used as a control versus glucose-free DMEM. After 24 h of incubation, glycogen was extracted, measured and corrected by protein content. Figure  3A shows that there was a total absence of glycogen content in HUVECs when glucose was absent from the culture medium. This dramatic decrease of glycogen content in glucose-free medium has been previously reported in other human endothelial cells (40) . Lactate production was also measured after 24 h. Its concentration decreased sharply in hypoglycaemic conditions (data not shown), indicating that glycogen reservoirs are not large enough to support glycolysis for 24 h.
Effects of hypoxia on HUVEC glycogen usage were also assessed. Corroboration of hypoxia impact in HUVEC metabolism was assessed by determining glucose and lactate from the culture medium, and the glycolytic rate was calculated as the rate of lactate production versus glucose consumption. As expected, after 24 h under hypoxic conditions (1% O 2 ), the glycolytic rate increased by 20%. This was also confirmed by a 37% increase in intracellular concentration of fructose-1,6-bisphosphate and measured as described previously (41) (data not shown). Glycogen content, however, was not metabolized in HUVECs under hypoxic condition, as observed in hypoglycaemia, but an increase in glycogen reservoirs was observed ( Figure 3B ).
PPP and glycogen metabolism are good antiangiogenic targets
Previously reported results suggested that glycogen metabolism and the PPP may be good targets for metabolic interventions (42) (43) (44) . Therefore, HUVECs were treated with CP-320626, an inhibitor of C enrichment, calculated as Rmn 5 2 Â m2, shows similar glycogen-glucose turnover after activation with both VEGF and FGF (black bars). The inhibitor (I: 5-diarylurea-oxy-benzimidazole) produced a significant decrease in glycogen turnover from glucose after VEGF-specific HUVEC activation (gray bars). After the FGF activation, the inhibitor did not significantly affect the total 13 C incorporation into glycogen. Significance was tested using a non-parametric Mann-Whitney W-test to compare the medians of each independent experiment, considering 99% as a confident level. Significant differences ( ÃÃ ) were consistent in the three independent experiments. (B) Glycogen content expressed in mg of glucose with respect to 10 6 cells. The inhibitor I promoted a significant accumulation of glycogen reservoirs. Significance ( Ã ) was tested using a non-parametric Mann-Whitney W-test to compare the medians of seven samples from two independent experiments, considering 95% as a confident level, 146 Â 168 mm (600 Â 600 DPI). Fig. 3 . Glycogen content, expressed as mg glucose released from glycogen with respect to mg of protein content, in HUVECs under hypoglycaemic or hypoxic culture conditions after 24 h. (A) hypoglycaemic conditions: the substitution of endothelial growth medium containing 10 mM of initial glucose by DMEM, 10 mM of initial glucose slightly affected the glycogen content in HUVECs. However, when glucose-free DMEM was used, HUVECs lost all of their glycogen reservoirs. (B) Hypoxic conditions (24 h at low O2 concentration) did not provoke the use of glycogen reservoirs, but caused a significant increase in cellular glycogen content. Significance ( ÃÃ ) was tested using a non-parametric Mann-Whitney W-test to compare the medians of five samples from two independent experiments, considering 99% as a confident level, 132 Â 170 mm (600 Â 600 DPI).
Metabolic modulation underlying angiogenesis the key enzyme in glycogen degradation, glycogen phosphorylase (45) , as well as with G5 and O1, inhibitors of glucose-6-phosphate dehydrogenase and transketolase, the key enzymes of the oxidative and non-oxidative branches of PPP (18), respectively. After 48 h, dose-escalating treatment with CP-320626 and both G5 and O1 caused dose-dependent inhibition of cell viability ( Figure 4A ), confirming the importance of these two metabolic pathways in HUVECs.
Moreover, the inhibitors of glycogen metabolism and PPP also impair the capacity of HUVEC to migrate ( Figure 4B ). After just 4 h of incubation, the addition of CP-320626 caused a decrease of migration of 12 and 84% at its respective IC50 and 10 Â IC50 concentration. Similar dose-response inhibition of PPP was observed, with a decrease of 40 and 66% for O1 and of 12 and 19% for G5 at their respective IC50 and 10 Â IC50 concentration. Consistent with proliferation assays, the inhibitor of the non-oxidative branch of PPP O1 decreased the migration capacity in a larger extend that G5 inhibitor of the oxidative branch of PPP. It could be explained by the metabolic characteristic of PPP: the non-oxidative branch of PPP is a reversible pathway with the capacity of buffering pentose with hexose phosphates, so the inhibition of the oxidative branch could be eventually compensated by the nonoxidative, provoking that increasing concentrations of G5 did not cause an massive increase in migration inhibition, as well as is observed in viability assays.
Discussion
Cancer is an extremely complex and heterogenous disease that exhibits a high level of robustness against a range of therapeutic efforts (46) . Looking for new targets to arrest cancer progression and invasion is one of the main current research challenges. With the development of systems biology, it has became more evident that a system level understanding of cancer cells and vascular endothelial cells that provide tumor vascularization could contribute to developing new drugs and therapies. Moreover, the recognition that the phenotype and function of mammalian cells largely depends on metabolic adaptation has greatly stimulated research initiatives in the field of metabolomics and fluxomics (20, 47) .
Although the central role of VEGF in the activation of angiogenesis has been clearly established, prior to the present study little was known about the metabolic network modulation required to support the angiogenic process. Results reported in this paper, using the [1,2-13 C 2 ]-glucose stable isotope as a carbon source and a tracerbased metabolomics approach, reveal a characteristic metabolic flux pattern downstream of endothelial cells activation, regardless of whether HUVECs are activated by VEGF or FGF. Thus, this common metabolic adaptation may be required to support endothelial cell function in the angiogenic process and includes a high flux of glucose through the PPP and an active glycogen metabolism. Lactate isotopomeric distribution is not significantly different when either VEGF or FGF is used to activate HUVECs (Table IA) . RNA ribose 13 C enrichment is slightly higher after FGF activation than after VEGF activation of HUVECs, probably due to a higher proliferation rate (Figure 1 ). However, fluxes through oxidative and non-oxidative branches of the pentose cycle are not significantly altered, as the oxidative:nonoxidative ratio was similar in all the experiments (Table IB, upper panel). Glycogen 13 C enrichment was $10% higher after FGF activation than after VEGF activation (Figure 2A ). This also correlates with a higher proliferation rate. This, and the fact that high, similar glycogen concentrations were found in VEGF-or FGF-activated HUVECs indicates that glycogen deposits are important for HUVEC proliferation.
This strong dependence of activated HUVEC metabolism on glycogen and the PPP could be essential to supporting the angiogenic process. Consequently, glycogen and the PPP could be targets within the angiogenic cell metabolic network for potential novel therapies. In order to check whether this common metabolic pattern is a consequence of the angiogenic HUVEC activation that may be essential for the angiogenic process, we analyzed the effects of a well-known VEGFR-2 inhibitor, 5-diarylurea-oxy-benzimidazole, on HUVECs' metabolic network. This inhibitor acts on the intracellular part of the VEGFR-2 and impedes phosphorylation through its tyrosine kinase activity, causing a decrease in the VEGF-activated phosphorylation cascade and the HUVEC proliferation rate (Figure 1) .
The lactate isotopomeric distribution did not change significantly when the inhibitor was added to either VEGF-activated or FGF-activated HUVECs (Table IA) , suggesting that glycolytic flux does not depend on signal transduction from the VEGF receptor. However, the results show that treatment with the inhibitor in VEGF-activated cells cause a decrease in PPP flux, as there was a significant decrease in 13 C ribose enrichment ( P mn) (Table IB) . This decrease was mainly determined by the inhibition of the oxidative branch of the PPP. Worthy of note, mass isotopomer distribution analysis experiments were performed at 72 h, when metabolic enrichment of 13 C from [1,2-13 C 2 ]-glucose is almost saturated. Therefore, the differences in proliferation rate caused by VEGF or FGF activation hardly led to a relevant difference in 13 C ribose enrichment. The specificity of this metabolic response is corroborated by the fact that the inhibitor treatment, which caused a 30 and 20% decrease in proliferation when HUVEC cells were activated with VEGF and FGF, respectively, only significantly decreased RNA ribose enrichment when VEGF was used as angiogenic activator. This leads us to conclude that the inhibitor acts specifically on its target receptor VEGFR-2, which causes a specific metabolic effect on PPP.
Interestingly, it has been demonstrated that activation of the pentose cycle is downregulated during the differentiation process (26) , whereas its activation is a common characteristic of tumor cells (48) . These results reinforce the emergence of the PPP as a promising therapeutic target, since actions on this pathway could inhibit tumor proliferation and impede angiogenic progression. Thus, metabolic inhibition of both the oxidative and non-oxidative branches of this pathway has been described as a good antitumoral strategy (18) (19) (20) (21) (22) . Moreover, it has been recently demonstrated that disruption of the balance between oxidative and non-oxidative branches of pentose phosphate metabolism using a multiple hit drug strategy results in colon cancer adenocarcinoma cell death (43) . Additionally, several studies have demonstrated that downregulation of these pathways decreases the migration capacity of bovine aortic endothelial cells (49, 50) .
The results also show that 5-diarylurea-oxy-benzimidazole inhibitor impairs 13 C enrichment of glycogen reservoirs when the inhibitor is added to VEGF-activated cells, but not when it is added to FGFactivated cells (Figure 2A, gray bars) , which led us to hypothesize a reducing glycogen mobilization specifically provoked by the inhibitor. This is confirmed by the accumulation of glycogen reservoirs when the inhibitor is present ( Figure 2B ).
The physiological impact of huge glycogen reservoirs on HUVECs could be explained by the needs of endothelial cells during the formation of new vessels, after their recruitment by solid tumors, in which there is a hypoglycaemic and hypoxic environment. Accordingly, by forcing physiological hypoglycaemic conditions, we observed how HUVEC glycogen reservoirs are totally catabolized ( Figure 3A) . Hypoxia does not lead to the use of glycogen reservoirs. On the contrary, it does cause an increase in the cellular glycogen content ( Figure 3B ). In hypoxic conditions, the glycolytic rate increases provoking an increase of the intracellular concentration of sugar phosphate glycolytic intermediates. Therefore, we hypothesize that the observed increase in glycogen content under hypoxic conditions could be explained by the metabolic equilibrium between glycolytic intermediates and glycogen reservoirs. Interestingly, glycogen metabolism has also been described as an antitumoral target in MIA pancreatic cells (42) , again providing a common, attackable metabolic characteristic in tumors and in the endothelial cells activated by them.
In summary, we have described high activity of pentose phosphate metabolism, large glycogen deposits and high glycogen turnover as a common adaptive metabolic pattern associated with angiogenic activation, regardless of the activation pathway. This proves the robustness of the angiogenic process ( Figure 5A ). Specific inhibition of the angiogenic stimulus using 5-diarylurea-oxy-benzimidazole resulted in a decrease in the PPP and glycogen metabolism, which confirms that the activation of these two pathways is one of the mechanisms resulting in angiogenic activation downstream of growth factor stimulation ( Figure 5B ). Thus, these results offer new insight into the vulnerability of the angiogenic cell metabolic network and indicate potential new antiangiogenic targets. To prove this hypothesis, we corroborated the importance of the aforementioned metabolic characteristics by inhibiting key enzymes to glycogen metabolism and PPP ( Figure 4 ) and corroborating that the inhibition affect both viability and migration capacity of HUVECs. Further work is needed to provide molecular evidence that directly links the observed metabolic changes to growth factor-signaling pathways and validates the new targets. Nevertheless, in this paper, we have demonstrated that metabolic studies can reliably provide a systemic view of a biological process, such as angiogenesis activation by growth factors, as well as the potential use of such processes for antiproliferative and anti-migration interventions. It is of crucial importance to note that the endothelial metabolic targets proposed here also promising anticancer targets (22, 42, 43) . Thus, metabolic interventions that could affect at the same time solid tumors and vessels formation should be seriously considered in integrating actions against carcinogenic process. 
